Paxton Bach1, Geoffrey Walton1, Kanna Hayashi1, M-J Milloy1, Huiru Dong1, Thomas Kerr1, Julio Montaner1, Evan Wood1. 1. Paxton Bach, Geoffrey Walton, M-J Milloy, Thomas Kerr, Julio Montaner, and Evan Wood are with the Department of Medicine, University of British Columbia, Vancouver, Canada. Kanna Hayashi, Huiru Dong, Thomas Kerr, Julio Montaner, and Evan Wood are with the British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada.
Abstract
OBJECTIVES: To examine the relationship between benzodiazepine (BZD) use and HCV seroconversion in 2 linked prospective cohorts of persons who inject drugs (PWID). METHODS: We examined prospective cohorts of 440 PWID (baseline BZD users: n = 102; 23.2%) from the AIDS Care Cohort to Evaluate Access to Survival Services (ACCESS) and the Vancouver Injection Drug Users Study (VIDUS) cohorts, followed-up from 1996 to 2013 in Vancouver, Canada. RESULTS: At baseline, the prevalence of HCV was higher among those who used BZD (80.5% vs 61.5%; P < .001). After adjustment, BZD use remained independently associated with increased rates of HCV seroconversion (adjusted rate ratio = 1.67; 95% confidence interval = 1.05, 2.66). CONCLUSIONS: BZD use is independently associated with HCV seroconversion in a population of PWID.
OBJECTIVES: To examine the relationship between benzodiazepine (BZD) use and HCV seroconversion in 2 linked prospective cohorts of persons who inject drugs (PWID). METHODS: We examined prospective cohorts of 440 PWID (baseline BZD users: n = 102; 23.2%) from the AIDS Care Cohort to Evaluate Access to Survival Services (ACCESS) and the Vancouver Injection Drug Users Study (VIDUS) cohorts, followed-up from 1996 to 2013 in Vancouver, Canada. RESULTS: At baseline, the prevalence of HCV was higher among those who used BZD (80.5% vs 61.5%; P < .001). After adjustment, BZD use remained independently associated with increased rates of HCV seroconversion (adjusted rate ratio = 1.67; 95% confidence interval = 1.05, 2.66). CONCLUSIONS:BZD use is independently associated with HCV seroconversion in a population of PWID.
Authors: S D Rosenberg; L A Goodman; F C Osher; M S Swartz; S M Essock; M I Butterfield; N T Constantine; G L Wolford; M P Salyers Journal: Am J Public Health Date: 2001-01 Impact factor: 9.308
Authors: Hudson Reddon; Kora DeBeck; M Eugenia Socias; Stephanie Lake; Huiru Dong; Mohammad Karamouzian; Kanna Hayashi; Thomas Kerr; M-J Milloy Journal: Am J Public Health Date: 2020-08-20 Impact factor: 9.308
Authors: Benjamin A Bouvier; Katherine M Waye; Beth Elston; Scott E Hadland; Traci C Green; Brandon D L Marshall Journal: Drug Alcohol Depend Date: 2017-12-07 Impact factor: 4.492
Authors: Lorenzo Zamboni; Igor Portoghese; Alessio Congiu; Thomas Zandonai; Rebecca Casari; Francesca Fusina; Anna Bertoldi; Fabio Lugoboni Journal: Front Psychiatry Date: 2022-01-25 Impact factor: 4.157